Publication date: May 23, 2025
Regarding PR exceeding eight weeks, the authors noted, some benefits may continue to accrue with extended PR, but no additional improvements in the 6MWT and lung function were observed. PR of four to eight weeks produced the most consistent improvements across physical capacity (6MWT), pulmonary function (FEV1, FVC), HRQOL, and fatigue. Across studies, PR consistently produced significant gains compared to controls in the 6-minute walking test (6MWT), 30-second sit-to-stand test, and handgrip strength test, indicating robust improvements in physical capacity. Programs shorter than four weeks yielded measurable improvements in the 6MWT, suggesting that even brief interventions confer a meaningful benefit, according to the authors. The authors underscored that these multidimensional benefits make PR an essential component of long COVID-19 management. Optimizing PR DurationDuration of PR emerged as a critical moderator of efficacy. HRQOL scores rose appreciably, while measures of dyspnea, fatigue, and anxiety declined following PR. Depression scores, however, did not differ significantly between groups.
| Concepts | Keywords |
|---|---|
| China | Benefits |
| Coughing | Breathing |
| Healthrelated | Capacity |
| University | Covid |
| Exercises | |
| Fatigue | |
| Found | |
| Hrqol | |
| Improvements | |
| Long | |
| Multicomponent | |
| Physical | |
| Pulmonary | |
| Rehabilitation | |
| Weeks |
Semantics
| Type | Source | Name |
|---|---|---|
| drug | DRUGBANK | Isoxaflutole |
| disease | IDO | role |
| disease | MESH | COVID-19 |
| disease | MESH | Depression |
| drug | DRUGBANK | Tropicamide |
| disease | MESH | syndromes |
| disease | MESH | dyspnea |
| disease | MESH | Long COVID |
| drug | DRUGBANK | Coenzyme M |
| disease | MESH | anxiety |
| disease | IDO | quality |